GlassScriptPhysician profile
Brytton L Long
NPI 1063709905
$3,161.32
in general payments reported to CMS, 2019-2025
30 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $282 · 2021: $668 · 2022: $520 · 2023: $364 · 2024: $612 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $482.54 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $325.99 | 2021-2025 | |
| Amgen INC. | $288.06 | 2019-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $227.07 | 2019-2025 | Verquvo, Capvaxive |
| Lilly USA, LLC | $201.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $175.89 | 2019-2025 | |
| Glaxosmithkline, LLC. | $156.23 | 2020-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $154.96 | 2019-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $140.01 | 2022-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $87.93 | 2023-2024 | Azstarys |
| Dexcom, INC. | $72.53 | 2024-2025 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $71.37 | 2021 | |
| Xeris Pharmaceuticals, INC. | $69.27 | 2021-2022 | |
| Amarin Pharma, INC. | $66.39 | 2020-2021 | |
| Lundbeck LLC | $62.26 | 2022-2025 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $62.12 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.44 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $56.24 | 2021-2025 | |
| Viatris Specialty LLC | $53.04 | 2025 | Yupelri |
| Eisai INC. | $50.36 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $48.27 | 2022 | |
| Ironshore Pharmaceuticals INC. | $47.96 | 2024 | |
| Mylan Specialty L.P. | $45.23 | 2024 | Yupelri |
| Collegium Pharmaceutical, INC. | $35.54 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.86 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.18 | 2023 | Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $22.56 | 2022 | |
| Exact Sciences Corporation | $14.83 | 2024 | Cologuard Collection Kit |
| Biogen, INC. | $12.58 | 2020 | |
| Gilead Sciences, INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brytton Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.